Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of fullerene or pharmaceutical salt thereof to prepare medicine used for treating pulmonary fibrosis

A technology of pulmonary fibrosis and fullerenes, applied in drug combinations, respiratory diseases, carbon active ingredients, etc., to achieve good safety and low toxic and side effects

Inactive Publication Date: 2017-11-07
CHINA JAPAN FRIENDSHIP HOSPITAL
View PDF8 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] However, there is currently no report on the use of fullerenes in the treatment of pulmonary fibrosis, especially IPF-induced pulmonary fibrosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of fullerene or pharmaceutical salt thereof to prepare medicine used for treating pulmonary fibrosis
  • Application of fullerene or pharmaceutical salt thereof to prepare medicine used for treating pulmonary fibrosis
  • Application of fullerene or pharmaceutical salt thereof to prepare medicine used for treating pulmonary fibrosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0059] Materials and methods

[0060] 1. Experimental animals: male C57BL / 6J mice aged 6-8 weeks, weighing 22-25 grams, purchased from Beijing Weitong Lihua Experimental Animal Technology Co., Ltd., and fed at the Basic Medical Research Center of Beijing Chaoyang Hospital Affiliated to Capital Medical University .

[0061] 2. Drugs and reagents

[0062]

[0063] 3. Animal model establishment

[0064] The present invention adopts the mouse pulmonary fibrosis model induced by bleomycin commonly used when studying pulmonary fibrosis and IPF [31] . The mice were weighed and anesthetized with 1% sodium pentobarbital (50mg / kg) intraperitoneally, fixed on the operating table in a supine position, routinely disinfected, a median neck incision was made, and the paratracheal muscles were bluntly dissected. Trachea: Use a 1ml syringe to slowly inject normal saline or bleomycin (3.5mg / kg [32] ) (the control group was injected with normal saline, and the other groups were injected ...

Embodiment 2

[0089] Example 2: Dose selection

[0090] Comparison of survival rate and body weight change in each group: On the 21st day after modeling, all mice in the normal control group survived, the survival rates of the BLM group and the low-dose intervention group were 30%, and the 10mg / kg C60 intervention group survived 66.7% (such as figure 1 ). From the body weight change curves of mice in each group (such as figure 2 ) shows that the body weight of the mice in the normal control group was significantly increased, the body weight of the BLM group was significantly decreased, and the body weight change of the 10mg / kg C60 intervention group was significantly better than that of the BLM group. This shows that 10mg / kg fullerene C60 can improve the survival rate of mice with pulmonary fibrosis and slow down the trend of weight loss in mice. Therefore, 10 mg / kg fullerene C60 was used as the selected dose in subsequent experiments.

Embodiment 3

[0091] Embodiment 3: Comparison of mouse lung CT results

[0092] On the 28th day of modeling, the lung CT findings of mice in each group were as follows: image 3 . The lung CT of the model group showed that the mediastinal window had a large amount of parenchymal filling, while the 10mg / kg C60 treatment group and the pirfenidone treatment group were significantly improved compared with the model group.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the field of pulmonary fibrosis treatment, and provides an application of fullerene or pharmaceutical salt thereof to prepare a medicine used for treating pulmonary fibrosis, wherein the fullerene or pharmaceutical salt exists in the medicine in a treatment effective amount.

Description

technical field [0001] The invention relates to the field of pulmonary fibrosis treatment, in particular to the application of fullerene or a pharmaceutically acceptable salt thereof in the preparation of medicines for treating pulmonary fibrosis. Background technique [0002] Pulmonary fibrosis (PF) refers to the final pathological outcome caused by factors such as necrosis of lung parenchymal cells, abnormal increase and excessive deposition of extracellular matrix in the tissue due to inflammation, mild cases lead to pulmonary tissue fibrosis, severe cases Organ sclerosis occurs due to the destruction of lung tissue structure. Pulmonary fibrosis can occur in a variety of settings, including unexplained stimuli, environmental or occupational exposure (eg, asbestos, silica), induced by drugs (eg, bleomycin), or secondary to other disorders, such as immune The complex can also induce pulmonary fibrosis. [0003] Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K33/44A61K47/44A61P11/00
CPCA61K33/44A61K47/44
Inventor 董润代华平刘敏
Owner CHINA JAPAN FRIENDSHIP HOSPITAL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com